pardoprunox (SLV-308) / AbbVie - LARVOL DELTA

5-HT agonists for levodopa-induced dyskinesia in Parkinson's disease. (PubMed, Neurodegener Dis Manag) - "Clinical trials testing 5-HT agonists have yielded inconsistent results in alleviating dyskinesia, especially that the antidyskinetic benefit observed was often accompanied by an adverse effect on motor function. In this article, we summarize and analyze the various clinical trials performed with 5-HT agonists in PD patients with dyskinesia and offer perspectives on the future of this class of agents in PD."

Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: Results of a double-blind, randomized, placebo-controlled, trial (Parkinsonism Relat Disord) - P3, N=294; NCT00406588; Pardoprunox reduced OFF time versus PBO(-1.62 h/day versus -0.92h/day, respectively, p=0.0215); Compared to PBO, pardoprunox improved ON time without troublesome dyskinesias (p=0.0386), UPDRS-ADL + Motor ON (p=0.0003), & UPDRS-ADL OFF (p<0.0001), while no difference was observed on PDQ-39

P3 data • Parkinson's Disease

Comprehensive Examination of Therapies for Pain in Parkinson's Disease: A Systematic Review and Meta-Analysis. (PubMed, Neuroepidemiology) - "Moderate effects in reducing pain were in pardoprunox and surgery, while the weakest effects were in dopaminergic agonists and miscellaneous therapies. Safinamide is an important adjunct to standard parkinsonian medication for alleviating pain in PD."

Journal • Retrospective data • Review